Redeye leaves an initial comment following the Q2 report published by Newbury this morning.
- Q1e: sales SEK 32m, up 3.7% y-o-y, EBIT margin of 19.
- Embla (name change from Ossur) reports Q1 on 23 April in morning - Solid start to 2024 with 5% Q1e...
Scanfil's valuation is 20% below the peer group median, but a small discount may be justified as lon...
Order intake likely to improve Sports & outdoor demand should normalise during '24 '24e-'26e EBIT up...
MGI – Media and Games Invest has announced a strategic collaboration with Google Cloud that will bri...
While IRLAB Therapeutics’ immediate focus is on advancing mesdopetam in levodopa-induced dyskinesia ...
Redeye views the news from Moberg Pharma that they have submitted an additional Terbinafine supplier...
Redeye provides preview on SSH Communications Security Q1 results scheduled for release on April 24.
Redeye offers a preview of Advenica's Q1 results set to be released on April 25th.
Q1 is a small quarter; we estimate SEK -9m adj. EBIT Small, mostly FX-driven revisions Kingspan got ...
Redeye comments on today’s news. Scibase has resolved a directed issue of c SEK 33m and a rights iss...
Pharma Equity Group (“PEG” or “the Company”) announced on Friday, April 5th, that the Company’s subs...
Cardeon är ett investmentbolag som investerar i bolag inom life science i tidig fas.
Duell’s H1/24 showed promising signs while uncertainties still remain ahead of the important H2.
Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were ...
Redeye leaves a comment following Faron’s announcement of a conducted private placement raising EUR4...
Core objectives, including divestments and securing bond refinancing completed One new divestment an...
Möter relativt lätta jämförelsetal BTS möter relativt enkla jämförelsetal i Q1’24.
Duell’s Q2 net sales came in at EUR 28.2m, above our estimate of EUR 25.
